BR0004709A - Quinolin-4-ila derivatives ii - Google Patents

Quinolin-4-ila derivatives ii

Info

Publication number
BR0004709A
BR0004709A BR0004709-0A BR0004709A BR0004709A BR 0004709 A BR0004709 A BR 0004709A BR 0004709 A BR0004709 A BR 0004709A BR 0004709 A BR0004709 A BR 0004709A
Authority
BR
Brazil
Prior art keywords
lower alkyl
amino
hydrogen
ila
quinolin
Prior art date
Application number
BR0004709-0A
Other languages
Portuguese (pt)
Inventor
Alexander Alanine
Serge Burner
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0004709A publication Critical patent/BR0004709A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE QUINOLIN-4-ILA II"<D>. A presente invenção refere-se a compostos da fórmula genérica onde R¹ é hidrogênio, alquila inferior, alcóxi inferior, hidróxi, amino, nitro, ciano, amino - alquila inferior, amino - alquila di - inferior ou halogênio; R² é hidrogênio, alquila inferior, amino, pirrolidin-3-ol, pirrolidin-2-ila, metanol ou -NHCH~ 2~CHROH; R³ é hidrogênio ou halogênio; R é hidrogênio, alquila inferior ou -CH~ 2~OH; n é 1 ou 2; e a seus sais de adição ácidos farmaceuticamente aceitáveis. Compostos da presente invenção são bloqueadores seletivos do subtipo receptor-NMDA(N-metil-D-aspartato), que têm uma função chave em modulação de atividade e plasticidade neuronal em processos de mediação subjacentes ao desenvolvimento de CNS assim como aprendizado e formação de memória.Invention Patent: <B> "QUINOLIN-4-ILA II DERIVATIVES" <D>. The present invention relates to compounds of the generic formula where R¹ is hydrogen, lower alkyl, lower alkoxy, hydroxy, amino, nitro, cyano, amino - lower alkyl, amino - lower alkyl or halogen; R² is hydrogen, lower alkyl, amino, pyrrolidin-3-ol, pyrrolidin-2-yl, methanol or -NHCH ~ 2 ~ CHROH; R³ is hydrogen or halogen; R is hydrogen, lower alkyl or -CH ~ 2 ~ OH; n is 1 or 2; and their pharmaceutically acceptable acid addition salts. Compounds of the present invention are selective blockers of the NMDA receptor subtype (N-methyl-D-aspartate), which have a key role in modulating neuronal activity and plasticity in mediation processes underlying the development of CNS as well as learning and memory formation .

BR0004709-0A 1999-10-08 2000-10-06 Quinolin-4-ila derivatives ii BR0004709A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99120131 1999-10-08

Publications (1)

Publication Number Publication Date
BR0004709A true BR0004709A (en) 2001-06-12

Family

ID=8239160

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0004709-0A BR0004709A (en) 1999-10-08 2000-10-06 Quinolin-4-ila derivatives ii

Country Status (26)

Country Link
US (1) US6339093B1 (en)
EP (1) EP1090917B1 (en)
JP (1) JP3385318B2 (en)
KR (1) KR100398562B1 (en)
CN (1) CN1162424C (en)
AR (1) AR032601A1 (en)
AT (1) ATE313538T1 (en)
AU (1) AU777881B2 (en)
BR (1) BR0004709A (en)
CA (1) CA2322309C (en)
DE (1) DE60024947T2 (en)
DK (1) DK1090917T3 (en)
EG (1) EG23872A (en)
ES (1) ES2254095T3 (en)
HR (1) HRP20000652A2 (en)
HU (1) HUP0003938A2 (en)
ID (1) ID27526A (en)
IL (1) IL138916A0 (en)
MA (1) MA26753A1 (en)
MX (1) MXPA00009771A (en)
NO (1) NO20005031L (en)
NZ (1) NZ507303A (en)
PE (1) PE20010660A1 (en)
PL (1) PL343057A1 (en)
TR (1) TR200002893A3 (en)
ZA (1) ZA200005447B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
AU2002250256B2 (en) * 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
US6831087B2 (en) 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
RS52495B (en) * 2007-06-18 2013-02-28 Richter Gedeon Nyrt. Sulfonyl-quinoline derivatives
CN103497114A (en) * 2007-06-29 2014-01-08 埃莫里大学 NMDA receptor antagonists for neuroprotection
CA2700841A1 (en) * 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
CA3023032A1 (en) * 2016-05-04 2017-11-09 Genoscience Pharma Substituted 2,4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
WO2018119374A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics Nmda receptor modulators and uses thereof
LT3830092T (en) 2018-08-03 2023-09-11 Novartis Ag Heteroaromatic nmda receptor modulators and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8409745D0 (en) * 1984-04-14 1984-05-23 Beecham Group Plc Active compounds
US4560692A (en) * 1984-07-18 1985-12-24 Hoffmann-La Roche Inc. 4-Piperidino-2-phenylquinolines
GB8716972D0 (en) * 1987-07-17 1987-08-26 Pfizer Ltd Treatment of cardiac arrhythmias
JPH0262875A (en) 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd Novel isoindoline derivative
US4992448A (en) * 1989-10-24 1991-02-12 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US5304554A (en) * 1990-04-27 1994-04-19 Emory University 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation
GB9203798D0 (en) * 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
GB9305644D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
US5567718A (en) * 1994-08-11 1996-10-22 Hoechst Marion Roussel Inc. 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives

Also Published As

Publication number Publication date
HRP20000652A2 (en) 2001-12-31
TR200002893A2 (en) 2001-04-20
DE60024947D1 (en) 2006-01-26
KR20010050915A (en) 2001-06-25
DE60024947T2 (en) 2006-09-21
ZA200005447B (en) 2001-04-09
CA2322309C (en) 2008-05-20
NO20005031L (en) 2001-04-09
CA2322309A1 (en) 2001-04-08
PE20010660A1 (en) 2001-06-26
AR032601A1 (en) 2003-11-19
MA26753A1 (en) 2004-12-20
PL343057A1 (en) 2001-04-09
JP3385318B2 (en) 2003-03-10
EP1090917A1 (en) 2001-04-11
DK1090917T3 (en) 2006-04-24
US6339093B1 (en) 2002-01-15
IL138916A0 (en) 2001-11-25
KR100398562B1 (en) 2003-09-19
CN1304936A (en) 2001-07-25
NZ507303A (en) 2002-09-27
AU6410000A (en) 2001-04-12
NO20005031D0 (en) 2000-10-06
EG23872A (en) 2007-11-27
JP2001114777A (en) 2001-04-24
HU0003938D0 (en) 2000-12-28
TR200002893A3 (en) 2001-04-20
CN1162424C (en) 2004-08-18
AU777881B2 (en) 2004-11-04
ID27526A (en) 2001-04-12
HUP0003938A2 (en) 2002-11-28
EP1090917B1 (en) 2005-12-21
MXPA00009771A (en) 2002-10-23
ATE313538T1 (en) 2006-01-15
ES2254095T3 (en) 2006-06-16

Similar Documents

Publication Publication Date Title
BR0004709A (en) Quinolin-4-ila derivatives ii
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
BRPI0409255A (en) 2- (8,9-dioxo-2,6-diazabi-cyclo (5.2.0) non-1 (7) -en-2-yl) alkylphosphonic acid derivatives and their use as d-aspartic receptor antagonists -n-methyl (nmda)
BR0113629A (en) Alpha4-mediated cell adhesion inhibitors
GB2369360A (en) 5-cyano-2-aminopyrimidine derivatives
NO20052989D0 (en) Therapeutic compounds.
BRPI0518581A2 (en) chromanylurea compounds that inhibit the vanilloid receptor subtype 1 receptor (vr1) and their uses
NZ512883A (en) 2-oxoquinoline compounds and medicinal uses thereof
BR0317600A (en) heteroarylalkanoic acids as derivatives of integrin receptor antagonists
MX2008013040A (en) Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (cb1) receptor ligands.
BR9916318A (en) Bicyclic compounds
WO2000012482A3 (en) Indazole derivatives with 5-ht2 receptor activity
BR0311410A (en) Piperidine Compound
BR0011865A (en) aromatic and heterocyclic derivatives of phytoterols and / or phytostanols for use in the treatment and prevention of cardiovascular disease
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
BR0209604A (en) 1-Oxa-3,9-diaza-spiro-5,5-undecan-2-ones derivatives and their use as a neuricinin receptor antagonist
BR0307521A (en) Alpha l beta2 integrin-mediated cell adhesion inhibitors
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
DK1136475T3 (en) Piperidine and piperazine derivatives for use in the treatment of Alzheimer&#39;s
BR9705509A (en) 4-hydroxy-piperidine derivatives.
BR0113348A (en) Nmda receptor ligand prodrugs
BR9813216A (en) Biesters of 1-oxa, aza and tianaftalen-2-ones as phospholamban inhibitors
ATE240329T1 (en) CYTOTOXIC PYRIDO(2,3,4-KL)ACRIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements